Compare FITBO & XOMAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Fifth Third Bancorp Depositary Shares each representing a 1/1000th ownership interest in a share of Non-Cumulative Perpetual Preferred Stock Series K
Current Price
| Metric | FITBO | XOMAO |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 18616 | 13 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | FITBO | XOMAO |
|---|---|---|
| Price | $19.76 | $25.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 15.3K | 1.7K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.19 | $23.32 |
| 52 Week High | $22.80 | $25.74 |
| Indicator | FITBO | XOMAO |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 55.68 |
| Support Level | $19.64 | $25.16 |
| Resistance Level | $19.85 | $25.65 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 19.44 | 77.80 |
Fifth Third Bancorp is a midsize regional bank in the US, with total assets of over $210 billion as of December 2025. The bank is set to close its acquisition of Comercia on Feb. 1, 2026. Headquartered in Cincinnati, Ohio, Fifth Third has a strong presence in the US Midwest and is currently expanding in the US Southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and Treasury management, wealth and asset management, and capital markets.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.